Advertisement

Topics

Latest "Cell Design Labs Appoints Chief Medical Officer" News Stories

09:48 EDT 19th October 2018 | BioPortfolio

Here are the most relevant search results for "Cell Design Labs Appoints Chief Medical Officer" found in our extensive news archives from over 250 global news sources.

More Information about Cell Design Labs Appoints Chief Medical Officer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Cell Design Labs Appoints Chief Medical Officer for you to read. Along with our medical data and news we also list Cell Design Labs Appoints Chief Medical Officer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Cell Design Labs Appoints Chief Medical Officer Companies for you to search.

Showing "Cell Design Labs Appoints Chief Medical Officer" News Articles 1–25 of 37,000+

Friday 19th October 2018

Herbalife Nutrition Scientists and Experts to Present Research and Best Practices at Upcoming Global Nutrition and Scientific Conferences

Herbalife Nutrition (NYSE: HLF), a premier global nutrition company whose purpose is to make the world healthier and happier, announced today that scientific leaders and experts, from its staff of more than 300 scientists and Ph.D.s, Nutrition Advisory Board and Herbalife Nutrition Institute editorial board, will participate at upcoming nutrition and ...


apceth Biopharma Presents Positive Data Demonstrating Efficacy of apceth-201 in Preclinial Models of Acute GvHD

Munich, Germany, October 19, 2018 / B3C newswire / -- apceth Biopharma GmbH, a company with the mission of improving patients’ lives with next generation cell therapies, announced today positive results for apceth-201 in mouse models for acute graft-versus-host disease (aGvHD). The data was highlighted in a poster presentation at the Annual Congress of the European Society of Gene and Cell Ther...

Halt Medical Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryHalt Medical Inc Halt Medical is a healthcare service center that develops, manufactures and commercializes medical treatment for women with symptomatic uterine fibroids. The center offers Acessa System, a minimally invasive laparoscopic outpatient procedure to treat uterine fibroids. It offers products for treatment of percutaneous, laparoscopic coagulation, ablation of soft tissue, and sy...


Adenosine Receptor A3 ADORA3 Pipeline Review, H2 2018 [Report Updated: 28092018] Prices from USD $3500

Adenosine Receptor A3 ADORA3 Pipeline Review, H2 2018SummaryAdenosine Receptor A3 ADORA3 pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Adenosine Receptor A3 ADORA3 Pipeline Review, H2 2018, outlays comprehensive information on the Adenosine Receptor A3 ADORA3 ta...

Siris Medical Announces Release of PlanMDTM Software, a New AI Decision Support Solution for Radiation Oncology

The new PlanMDTM software introduces real-time prescriptive contouring to enable faster, smarter treatment planning and better outcomes Siris Medical, Inc., headquartered in Silicon Valley and Boston, offers the only Artificial Intelligence (AI) treatment decision-support system for use in radiation oncology. The new PlanMDTM software enables ra...

Canon Medical Showcases FDA-Cleared Aquilion Precision at ASTRO 2018

Ultra-High Resolution CT System May Help Expand Visualization of Disease At this year’s American Society of Radiation Oncology (ASTRO) annual meeting in San Antonio, Texas, October 21-24, 2018 (Booth #3737), Canon Medical Systems USA, Inc. will showcase its recently FDA-cleared Aquilion PrecisionTM, the world’s first Ultra-High Resolution CT system...

RelayHealth Pharmacy Solutions Strengthens Retail Pharmacies’ Efforts to Expand Clinical Services with Medical Billing Platform in Collaboration with STRAND Clinical Technologies

New platform simplifies pharmacy reimbursement process for clinical services covered under a medical benefit RelayHealth Pharmacy Solutions, part of the McKesson Prescription Technology Solutions business,

WaferGen Biosystems Inc Medical Equipment Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryWaferGen Biosystems Inc WaferGen is a biotechnology Company which develops, manufactures and sells systems for genomic technology solutions for singlecell analysis and clinical research. The Company's ICELL8 SingleCell System platform isolates single cells and process specific cells for analysis, including Next Generation Sequencing NGS. The Company's SmartChip platform is used for profilin...

Researchers Discover New Genetic Disease

NewsResearchers have discovered a new genetic disease and a method for detecting more unexplained medical conditions.Contributed Author: 

NEJM retracts article from former researcher once hailed as heart stem cell pioneer

The New England Journal of Medicine has retracted one paper1 and issued an “expression of concern” about two others2 within days of Harvard Medical School and Brigham and Women’s Hospital announcing...

Nordson buys Irish firm Clada Medical Devices

Based in Galway, Clada Medical Devices is engaged in the designing and development of balloons and balloon catheters. Terms of the deal have not been disclosed. With a The post Nordson buys Irish firm Clada Medical Devices appeared first on Compelo Medical Devices.

Viseon gets FDA nod for Voyant system for minimally invasive spine surgery

The Voyant system features proprietary HD imaging sensor and illumination technology. The Voyant system is composed of a sterile single-use, disposable retractor device with integrated state-of-the-art visualization technology, The post Viseon gets FDA nod for Voyant system for minimally invasive spine surgery appeared first on Compelo Medical Devices.

Synoste secures €5.1m to develop smart skeletal deformation correction technology

The company is engaged in the development of smart solutions for patient-friendly bone-lengthening and bone-deformation correction. Synoste’s patented technology platform provides the basis for further disruptive changes in The post Synoste secures €5.1m to develop smart skeletal deformation correction technology appeared first on Compelo Medical Devices.

Atrium Medical to sell biosurgery business to SeCQure Surgical’s subsidiary

Atrium Medical stated that the sale is expected to close in the fourth quarter of this year, subject to customary closing conditions and the receipt of regulatory approvals. The post Atrium Medical to sell biosurgery business to SeCQure Surgical’s subsidiary appeared first on Compelo Medical Devices.

Deciphera Pharmaceuticals Reports Updated Preliminary Phase 1 Clinical Study Results with DCC-2618 at the European Society of Medical Oncology (ESMO) 2018 Congress

- Preliminary Median Progression Free Survival and Disease Control Rates from the Phase 1 Study of DCC-2618 in Second- and Third-Line GIST Patients Demonstrate the Potential for Improved and Durable Clinical Outcomes in Patients with Less Advanced Disease - - Updated Objective Response Rates and Disease Control Rates Observed in these Preliminary ...

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer

– In Patients with Brain Metastases at Baseline, ALUNBRIG Reduced the Risk of Progression in the Brain or Death by 73 Percent – – Intracranial Efficacy Data Reinforces Superiority of ALUNBRIG Versus Crizotinib in the First-Line Treatment Setting – – Data Will Be Presented in a Poster Discussion at the European Society for Medica...

Medical Marijuana Use in a Community Cancer Center

About 20% of patients receiving chemotherapy are using marijuana according to a new study. Is use associated with cancer stage? Journal of Oncology Practice

PolyNovo Biomaterials Pty Ltd Product Pipeline Analysis, 2018 Update [Report Updated: 12092018] Prices from USD $750

SummaryPolyNovo Biomaterials Pty Ltd PolyNovo, a subsidiary of PolyNovo Ltd is a medical technology company that develops, designs and manufactures controlled bioeroding tissue and orthopedic solutions. The company's Novosorb polymers are based on polyurethanes, a polymer family used in medical and industrial applications. Its product is used in the areas of skin mimetic and extracellular matrix s...

Orbita Takes Steps to Drive Innovation in Conversational AI and Voice Technology Solutions for Health Care

Voice solution provider now working with academic medical center to explore opportunities to improve patient care. BOSTON (PRWEB) October 19, 2018 Orbita and team members from Brigham and Women’s Hospital Digital Innovation Hub will be working together to explore and advance the use of voice-enabled and conversational AI solutions in health care. The organizations will collaborate on innovation...

DJO Global Inc Medical Equipment Deals and Alliances Profile [Report Updated: 12092018] Prices from USD $250

SummaryDJO Global Inc. DJO is a medical device company. The company engages in provision of orthopaedic devices. DIO develops, manufactures and distributors orthopaedic devices for musculoskeletal health, vascular health and pain management solutions. The company products include rigid and soft orthopaedic bracing, bone growth stimulators, vascular therapy systems and compression garments. DJO Glo...

PrEView of cell–cell communication

TP Therapeutics Completes $80 Million Mezzanine Financing Co-Led by Foresite Capital and venBio Partners

Dr. Athena Countouriotis Promoted to Chief Executive Officer and Member of the Board of Directors Dr. Peter Li Named Head of TP Therapeutics Asia TP Therapeutics, a clinical-stage precision oncology company developing novel drugs that address treatment resistance, today announced its completion of an $80 million round of mezzanine fi...

Appointment Ludo Gielen as new CEO Schoeller Allibert

We are pleased to announce the appointment of Ludo Gielen as new Chief Executive Officer of Schoeller Allibert effective 01 November 2018... The post Appointment Ludo Gielen as new CEO Schoeller Allibert appea

The Return of the Miscellany of Medical Malarkey Strikes Back

The flu season is upon us, as is the first pediatric death. A polio-like illness is spreading, and experts are baffled. Kids probably shouldn't be around giant spinning metallic blades. Magic tape! You guessed it, another miscellany of medical malarkey has risen from the grave.

Rocket Pharmaceuticals Presents Preclinical Data at the 2018 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)

- Promising Preclinical Results from Leukocyte Adhesion Deficiency-I and Infantile Malignant Osteopetrosis Programs – - Leukocyte Adhesion Deficiency-I Program On Track to Enter Clinic in 2019; Infantile Malignant Osteopetrosis Program in 2020- Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading U.S.-based multi-plat...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks